Adverse effects of fructose on cardiometabolic risk factors and hepatic lipid metabolism in subjects with abdominal obesity (360 views)
J Intern Med (ISSN: 0954-6820), 2017 May 26; N/D: N/D-N/D.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 6.754, 5-year impact factor: 7.018
Url: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85021364651&doi=10.1111%2fjoim.12632&partnerID=40&md5=3e2c3a69cebb657594f143303ec6c753
Keywords: Nafld, De Novo Lipogenesis, Fructose, Obesity, Triglyceride-Rich Lipoproteins,
Affiliations:
*** IBB - CNR ***
Research Programs Unit, Diabetes and Obesity, University of Helsinki and Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland., Institute for Molecular Medicine FIMM, Helsinki, Finland., Department of Public Health, University of Helsinki, Helsinki, Finland., Department of Radiology, HUS Medical Imaging Center, Helsinki University Central Hospital, University of Helsinki, Finland., Endocrinology, Abdominal Center, Helsinki University Hospital, Helsinki, Finland., Department of Molecular and Clinical Medicine/Wallenberg Laboratory, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden., Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Quebec City, Quebec, Canada., Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy., Biostructure and Bioimaging Institute, National Research Council, Naples, Italy.,
References:
Not available.
J Intern Med (ISSN: 0954-6820), 2017 May 26; N/D: N/D-N/D.
Export to BibTeX Export to EndNote
Paper type: Journal Article,
Impact factor: 6.754, 5-year impact factor: 7.018
Url: https://www.scopus.com/inward/record.uri?eid=2-s2.0-85021364651&doi=10.1111%2fjoim.12632&partnerID=40&md5=3e2c3a69cebb657594f143303ec6c753
Keywords: Nafld, De Novo Lipogenesis, Fructose, Obesity, Triglyceride-Rich Lipoproteins,
Affiliations:
*** IBB - CNR ***
Research Programs Unit, Diabetes and Obesity, University of Helsinki and Heart and Lung Center, Helsinki University Hospital, Helsinki, Finland., Institute for Molecular Medicine FIMM, Helsinki, Finland., Department of Public Health, University of Helsinki, Helsinki, Finland., Department of Radiology, HUS Medical Imaging Center, Helsinki University Central Hospital, University of Helsinki, Finland., Endocrinology, Abdominal Center, Helsinki University Hospital, Helsinki, Finland., Department of Molecular and Clinical Medicine/Wallenberg Laboratory, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden., Institut Universitaire de Cardiologie et de Pneumologie de Quebec, Quebec City, Quebec, Canada., Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy., Biostructure and Bioimaging Institute, National Research Council, Naples, Italy.,
References:
Not available.
Adverse effects of fructose on cardiometabolic risk factors and hepatic lipid metabolism in subjects with abdominal obesity
BACKGROUND: Overconsumption of dietary sugars, fructose in particular, is linked to cardiovascular risk factors such as type 2 diabetes, obesity, dyslipidemia, and non-alcoholic fatty liver disease. However, clinical studies have to date not clarified whether these adverse cardiometabolic effects are induced directly by dietary sugars, or if they are secondary to weight gain. OBJECTIVES: To assess the effects of fructose (75 g/day), served with their habitual diet over 12 weeks, on liver fat content and other cardiometabolic risk factors in a large cohort (n=71) of abdominally obese men. METHODS: We analyzed changes in body composition, dietary intake, an extensive panel of cardiometabolic risk markers, hepatic de novo lipogenesis (DNL), liver fat content, and postprandial lipid responses after a standardized oral fat tolerance test (OFTT). RESULTS: Fructose consumption had modest adverse effects on cardiometabolic risk factors. However, fructose consumption significantly increased liver fat content and hepatic DNL and decreased beta-hydroxybutyrate (a measure of beta-oxidation). The individual changes in liver fat were highly variable in subjects matched for the same level of weight change. The increase in liver fat content was significantly more pronounced than the weight gain. The increase in DNL correlated positively with triglyceride area under the curve responses after an OFTT. CONCLUSION: Our data demonstrated adverse effects of moderate fructose consumption for 12 weeks on multiple cardiometabolic risk factors in particular on liver fat content despite only relative low increases in weight and waist circumference. Our study also indicates that there are remarkable individual differences in susceptibility to visceral adiposity/liver fat after real world daily consumption of fructose sweetened beverages over 12 weeks. This article is protected by copyright. All rights reserved.
BACKGROUND: Overconsumption of dietary sugars, fructose in particular, is linked to cardiovascular risk factors such as type 2 diabetes, obesity, dyslipidemia, and non-alcoholic fatty liver disease. However, clinical studies have to date not clarified whether these adverse cardiometabolic effects are induced directly by dietary sugars, or if they are secondary to weight gain. OBJECTIVES: To assess the effects of fructose (75 g/day), served with their habitual diet over 12 weeks, on liver fat content and other cardiometabolic risk factors in a large cohort (n=71) of abdominally obese men. METHODS: We analyzed changes in body composition, dietary intake, an extensive panel of cardiometabolic risk markers, hepatic de novo lipogenesis (DNL), liver fat content, and postprandial lipid responses after a standardized oral fat tolerance test (OFTT). RESULTS: Fructose consumption had modest adverse effects on cardiometabolic risk factors. However, fructose consumption significantly increased liver fat content and hepatic DNL and decreased beta-hydroxybutyrate (a measure of beta-oxidation). The individual changes in liver fat were highly variable in subjects matched for the same level of weight change. The increase in liver fat content was significantly more pronounced than the weight gain. The increase in DNL correlated positively with triglyceride area under the curve responses after an OFTT. CONCLUSION: Our data demonstrated adverse effects of moderate fructose consumption for 12 weeks on multiple cardiometabolic risk factors in particular on liver fat content despite only relative low increases in weight and waist circumference. Our study also indicates that there are remarkable individual differences in susceptibility to visceral adiposity/liver fat after real world daily consumption of fructose sweetened beverages over 12 weeks. This article is protected by copyright. All rights reserved.
Adverse effects of fructose on cardiometabolic risk factors and hepatic lipid metabolism in subjects with abdominal obesity
No results. |
Adverse effects of fructose on cardiometabolic risk factors and hepatic lipid metabolism in subjects with abdominal obesity
Other filter: ([btitle,keywords] "De Novo Lipogenesis" ...
Bozzetto L, Costabile G, Luongo D, Naviglio D, Cicala V, Piantadosi C, Patti L, Cipriano P, Annuzzi G, Rivellese AA
* Reduction in liver fat by dietary MUFA in type 2 diabetes is helped by enhanced hepatic fat oxidation (358 views)
Diabetologia (ISSN: 0012-186x), 2016 Dec; 59(12): 2697-2701.
Impact Factor: 6.08
View Export to BibTeX Export to EndNote
* Reduction in liver fat by dietary MUFA in type 2 diabetes is helped by enhanced hepatic fat oxidation (358 views)
Diabetologia (ISSN: 0012-186x), 2016 Dec; 59(12): 2697-2701.
Impact Factor: 6.08
View Export to BibTeX Export to EndNote
1 Records (1 excluding Abstracts).
Total impact factor: 6.08 (6.08 excluding Abstracts).
Total 5 year impact factor: 6.358 (6.358 excluding Abstracts).
Total impact factor: 6.08 (6.08 excluding Abstracts).
Total 5 year impact factor: 6.358 (6.358 excluding Abstracts).
360 views. Last view on Sunday 01 December 2024, 6:31:59
ibb.cnr.it
